Rani Therapeutics Inc. (RANI)
The price, the headline numbers and the latest news, in one place.
Rani Therapeutics Inc. (RANI) Stock Price, Analysis & Data
| Bid | 0.76 |
| Market Cap | 125.2M |
| Revenue (ttm) | 4.88M |
| Net Income (ttm) | -30.14M |
| 0.69 | |
| -0.13 | |
| n/a | |
| -4.69 | |
| P/B (ttm) | 3.13 |
| P/S (ttm) | 25.67 |
| Earnings Date | Nov 5, 2026 |
| Ask | 1 |
| Volume | 782,297 |
| Avg. Volume (20D) | 867,033 |
| Open | 0.89 |
| Previous Close | 0.88 |
| Day's Range | 0.86 - 0.90 |
| 52-Week Range | 0.44 - 3.87 |
| Analyst | Strong Buy |
| Price Target | 6 (574.16%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, protei...
Financial Performance
In 2025, Rani Therapeutics's revenue was 1.63M, an increase of 58.85% compared to the previous year's 1.03M. Earnings were -29.67M, a decrease of -1.15%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for RANI stock is "Strong Buy". The 12-month stock price forecast is 6, which is upside of 574.16% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.71M misses estimates by $0, with 893.02% YoY growth.
- EPS of -0.04 exceeds estimates by 0.01, with 77.78% YoY growth.
Analysts project revenue of ... Upgrade
